Left for Dead Valeant Pharma (VRX) Is Up 30% In a Week

Short seller target Valeant Pharma (NYSE: VRX) is continuing to rally sharply off oversold conditions following a few modest positives over the past week or so:

• Citi launched coverage on the debt with an Overweight rating
• Valeant products are selling ex-Philidor
• Valeant to offer cash, stock to keep staff after turmoil
• Positive analyst comments: Morgan Stanley, Mizuho

While nothing is a huge positive catalyst in and of itself, taken together the positives are enough to persuade shorts to lock in gains and move on.

Shares are up 6.5% today and 29% since the start of last week.

You May Also Be Interested In

• Pelican Way Research shorts Hyliion Holdings (HYLN) on VFG deal concerns
• EG Group confidentially filed for $1 billion U.S. IPO - Bloomberg
• Alibaba Sues US For Removal From China Military Blacklist - Bloomberg